AbbVie $ABBV has obtained FDA approval to administer its Mavyret hepatitis C pill as a two-month regimen, versus the 12-week course it was originally cleared for — a move that may help expand options for the margin of covered patients who need a shorter regimen.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,